Skip to Main content Skip to Navigation
Journal articles

Toxicité rénale des antiangiogéniques [Renal toxicity of anti-VEGF (corrected) targeted therapies].

Cécile Vigneau 1, * Nathalie Rioux-Leclercq 1
* Corresponding author
1 Cancer du rein : bases moléculaires de la tumorogenèse
IGDR - Institut de Génétique et Développement de Rennes
Abstract : For a few years, new targeted therapies have been used for metastatic cancers, targeting VEGF and its receptors and improving patients' survival for metastatic carcinoma (kidney, GIST, breast, colorectal). The objective of these treatments is to block either circulating VEGF (bevacizumab; VEGF-Trap), or tyrosine kinase receptors (especially the VEGF receptor) (sorafenib, sunitinib, brivanib, imatinib, etc.). Indeed, VEGF stimulates endothelial cell proliferation and then tumour growth and metastasis. However, all these antiangiogenic drugs share similar side effects, most frequently gastrointestinal disturbance, skin toxicity and hypertension. Hypertension seems to be especially frequent in case of good response. Renal side effects have probably been underestimated in the first place and their exact frequency is not known, needing some specific trials and registries. Proteinuria, thrombotic microangiopathies and acute renal failures have been reported: renal biopsies might be necessary for precise evaluation of renal damages. Physiopathology seems very close to preeclampsia. Good collaboration between oncologists, nephrologists and cardiologists is therefore crucial in order to continue these targeted therapies safely for the patients.
Document type :
Journal articles
Complete list of metadatas

https://hal-univ-rennes1.archives-ouvertes.fr/hal-00877129
Contributor : Clémence Martin <>
Submitted on : Saturday, October 26, 2013 - 12:44:21 PM
Last modification on : Wednesday, October 14, 2020 - 3:55:33 AM

Identifiers

Citation

Cécile Vigneau, Nathalie Rioux-Leclercq. Toxicité rénale des antiangiogéniques [Renal toxicity of anti-VEGF (corrected) targeted therapies].. Néphrologie et Thérapeutique, Elsevier Masson, 2013, 9 (3), pp.174-9. ⟨10.1016/j.nephro.2012.10.003⟩. ⟨hal-00877129⟩

Share

Metrics

Record views

126